1 From the Departments of Medicine and Pharmacology, University of Kansas Medical Center, Kansas City, Kansas.
Clofibrate was administered to 45 patients for varying periods of time up to 4 years with no evidence of chronic toxicity. Clofibrate was more effective in lowering serum triglycerides than serum cholesterol, with more than 75% of all patients with elevated triglycerides having at least a 25% reduction in triglycerides, the absolute reduction in triglycerides being directly correlated with pretreatment values. A reduction in serum cholesterol of 15% or more was obtained in 50% of all patients, those individuals with elevations of triglycerides having the greatest reduction in serum cholesterol as well as being most likely to respond.
© 1969 American Heart Association, Inc.
Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in Man
Key Words: Hyperlipidemia therapy
This article has been cited by other articles:
![]() |
L. K. SMITH, R. V. LUEPKER, S. S. ROTHCHILD, A. GILLIS, L. KOCHMAN, and J. R. WARBASSE Management of Type IV Hyperlipoproteinemia: Evaluation of Practical Clinical Approaches Ann Intern Med, January 1, 1976; 84(1): 22 - 28. [Abstract] [PDF] |
||||
![]() |
The Coronary Drug Project Research Group Clofibrate and Niacin in Coronary Heart Disease JAMA, January 27, 1975; 231(4): 360 - 381. [Abstract] [PDF] |
||||
![]() |
R. I. LEVY, D. S. FREDRICKSON, R. SHULMAN, D. W. BILHEIMER, J. L. BRESLOW, N. J. STONE, S. E. LUX, H. R. SLOAN, R. M. KRAUSS, and P. N. HERBERT Dietary and Drug Treatment of Primary Hyperlipoproteinemia Ann Intern Med, August 1, 1972; 77(2): 267 - 294. [Abstract] [PDF] |
||||
![]() |
D. Berkowitz Long-Term Treatment of Hyperlipidemic Patients With Clofibrate JAMA, November 15, 1971; 218(7): 1002 - 1005. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1969 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |